IMGN News and Press, ImmunoGen Inc. From 11/30/23

2023-11-30 14:54:50 ET Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share of Im...

2023-11-30 12:41:00 ET Summary OPEC+ agrees to an additional cut of 1M bpd, boosting oil prices. AbbVie to buy Immunogen for about $10B in cash. J.P. Morgan Chase's equity team is out with a bearish target for stocks next year. Listen below or on the go on Apple Po...

2023-11-30 12:33:37 ET Gainers: Smart for Life ( SMFL ) +159% . Immunogen ( IMGN ) +82% . Ampio Pharmaceuticals ( AMPE ) +68% . REX American Resources Corp ( REX ) +36% . ShiftPixy ( PIXY ) +31% . Digital Brands Group ( DBG...

2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...

ImmunoGen, Inc. (NASDAQ: IMGN) is one today's most active stocks by volume. So far today, approximately 5.48M shares of ImmunoGen, Inc. have been exchanged, as compared to an average 30-day volume of 4.91M shares. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug ...

2023-11-30 09:45:00 ET Summary AbbVie's ex-Humira growth products showed solid growth in Q3, boosting management's confidence in their success. The company upgraded its guidance, raised its full-year revenue estimates, and adjusted its EPS outlook. AbbVie stock has been impact...

2023-11-30 08:52:00 ET U.S. stock index futures on Thursday pointed to a higher open, after economic data showed a moderation in the Federal Reserve's favorite inflation gauge. On the final day of November, markets are on track to close out their best monthly performance since July 2022...

2023-11-30 07:42:10 ET More on AbbVie, ImmunoGen, etc. AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024 AbbVie repo...

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio PR Newswire Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE ®...

2023-11-27 17:41:15 ET Summary ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-high platinum-resistant ovarian cancer expected late...